| Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma (NCT05845632) | Maastricht University Medical Center | 2022-01-01 |
| Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma (NCT03799744) | Institut Català d'Oncologia | 2019-03-20 |
| Smoking Tobacco Cessation Integrated Program of Patients Treated for the Head and the Neck Cancer (NCT03788785) | Assistance Publique - Hôpitaux de Paris | 2019-03-09 |
| A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (NCT03735290) | Mendus | 2019-01-14 |
| Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer (NCT03715946) | Robert L. Ferris, MD, PhD | 2018-11-16 |
| A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck (NCT03620123) | AIO-Studien-gGmbH | 2018-07-16 |
| ctDNA as a Biomarker for Treatment Response in HNSCC (NCT03540563) | The Netherlands Cancer Institute | 2018-07-16 |
| Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (NCT03485209) | Seagen, a wholly owned subsidiary of Pfizer | 2018-06-25 |
| Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (NCT03509012) | AstraZeneca | 2018-05-02 |
| Biomarker-based Study in R/M SCCHN (NCT03088059) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-11-16 |
| Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC (NCT03291002) | CureVac | 2017-09-25 |
| NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT03109158) | NanoCarrier Co., Ltd. | 2017-03-01 |
| Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) (NCT02938273) | The Netherlands Cancer Institute | 2017-02-01 |
| Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (NCT02822482) | UNICANCER | 2016-06-01 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (NCT02658214) | AstraZeneca | 2016-04-28 |
| Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy (NCT02753140) | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2016-04-01 |
| Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck (NCT02289209) | Dan Zandberg | 2016-03-09 |
| Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC (NCT02585973) | UNC Lineberger Comprehensive Cancer Center | 2015-10-26 |
| Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT02277184) | Julie E. Bauman, MD, MPH | 2015-09-01 |
| Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT02277197) | James J Lee | 2015-08-01 |
| Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer (NCT02383966) | Merck KGaA, Darmstadt, Germany | 2015-07-31 |
| Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT02438995) | Northwell Health | 2015-05-01 |
| Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma (NCT02296684) | Washington University School of Medicine | 2015-03-25 |
| Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck (NCT02113878) | Dana-Farber Cancer Institute | 2014-09-29 |
| PD 0332991 and Cetuximab in Patients With Incurable SCCHN (NCT02101034) | Washington University School of Medicine | 2014-06-17 |
| State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study (NCT02242916) | Maastricht Radiation Oncology | 2014-05-01 |
| CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer (NCT02052960) | Glycotope GmbH | 2014-02-01 |
| Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT01836029) | Celgene | 2013-10-14 |
| A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy (NCT01876693) | Mahidol University | 2013-05-01 |
| Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck (NCT01538381) | European Organisation for Research and Treatment of Cancer - EORTC | 2012-07-01 |
| Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer (NCT02655068) | University of Pittsburgh | 2012-05-01 |
| A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer. (NCT01606566) | PCI Biotech AS | 2012-04-01 |
| Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma (NCT00903461) | University of Pittsburgh | 2012-04-01 |
| Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients (NCT01415674) | UNICANCER | 2012-01-01 |
| Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer (NCT01588431) | The University of Texas Health Science Center at San Antonio | 2011-12-01 |
| Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy (NCT01417936) | Symphogen A/S | 2011-07-01 |
| A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab (NCT01307267) | Pfizer | 2011-06-21 |
| A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN) (NCT01080066) | Merck KGaA, Darmstadt, Germany | 2010-09-01 |
| A Phase 1 Study in Participants With Advanced Cancer (NCT01115790) | Eli Lilly and Company | 2010-02-01 |
| Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer (NCT00957086) | National Cancer Centre, Singapore | 2009-08-13 |
| Treatment of Advanced Head and Neck Cancer (NCT00982696) | Milton S. Hershey Medical Center | 2008-02-01 |
| Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer (NCT00412776) | Sesen Bio, Inc. | 2005-12-01 |